Researchers have identified 69 compounds which may be effective in targeting SARS-CoV-2 including 29 FDA-approved drugs, 12 drugs in clinical trials and 28 preclinical compounds.
Gordon, D.E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature (2020). DOI: 10.1038/s41586-020-2286-9
30 April 2020
In this article, researchers systematically investigated the host dependencies of the SARS-CoV-2 virus. They reasoned that existing drugs may already target these host components and that mutation resistance is less likely to arise at the host-virus interface, since this interaction is required for the virus to infect and replicate in host cells. Using a screening approach, the authors identified 332 interactions between SARS-CoV-2 proteins and host cell proteins. They then screened chemical databases and relevant literature to identify drugs and reagents that act on these host factors. 69 potential compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials and 28 preclinical compounds were then tested to see whether they could block infection of host cells by SARS-CoV-2. The authors report that targeting viral protein synthesis or an infected cell’s ‘stress response’ was the most effective antiviral strategy at the cellular level. Ultimately, this drug discovery pipeline highlights clinically actionable drugs that warrant further study for both coronavirus and pan-viral therapies.
Summary by: Sivakami Mylvaganam